Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IFN‐α treatment may enable discontinuation of TKIs in NK cell‐licensed patients with CML‐CP

26 Nov 2024

Abstract excerpt

Abstract The magnitude of the natural killer (NK) cell response contributes to the achievement of treatment‐free remission (TFR) in patients with chronic myeloid leukemia (CML) and is regulated by the interaction between killer immunoglobulin‐like receptors (KIRs) on NK cells and human leukocyte antigen (HLA) class I molecules on target cells. The abundant combination between KIR and HLA through genetic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Chronic Myeloid Leukemia Treatments
Share to Immune Cell Function and Interaction
Share to T-cell and B-cell Immunology

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39691242
DOI: 10.1002/jha2.1053

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IFN‐α treatment may enable discontinuation of TKIs in NK cell‐licensed patients with CML‐CPPMID 39691242Read ↗

HLA Polymorphisms Are Associated with Treatment-Free Remission Following Discontinuation of Tyrosine Kinase Inhibitors in Chronic Myeloid LeukemiaSemantic proximity Read ↗

Allelic Polymorphisms of KIRs and HLAs Predict Favorable Responses to Tyrosine Kinase Inhibitors in CML.Semantic proximity Read ↗

Allelic polymorphisms of KIRs and antitumor immunity against chronic myeloid leukemia.Semantic proximity Read ↗

KIR3DL1 Allotype-Dependent Modulation of NK Cell Immunity against Chronic Myeloid Leukemia.Semantic proximity Read ↗

Human NK receptors: From the molecules to the therapy of high risk leukemiasSemantic proximity Read ↗

Molecular relapse monitoring reveals the domination of impaired NK cell education over impaired inhibition in missing KIR-ligand recognition in patients after unrelated hematopoietic stem cell transplantation for malignant diseases.Semantic proximity Read ↗

Natural killer cell receptors and ligand variants modulate response to tyrosine kinase inhibitors in patients with chronic myeloid leukemia.Semantic proximity Read ↗

[Gene KIR in match with HLA-Cw impacts on NK cell cytotoxicity].Semantic proximity Read ↗

Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT.Semantic proximity Read ↗

KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.Semantic proximity Read ↗

Homozygosity for killer immunoglobin-like receptor haplotype A predicts complete molecular response to treatment with tyrosine kinase inhibitors in chronic myeloid leukemia patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.